Mavacamten (Camzyos): A Short Guide to the Drug That Relaxes an Overpowered Heart
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Mavacamten (Camzyos): A Short Guide to the Drug That Relaxes an Overpowered Heart

A guide to mavacamten (Camzyos): the first drug to act on the mechanics of excessive heart contraction in obstructive hypertrophic cardiomyopathy; in EXPLORER-HCM it improved functional class and exercise capacity significantly more often than placebo. How to take it, echocardiography monitoring, the REMS programme, who should see a doctor first, and how aficamten differs.

Mavacamten (Camzyos): A Short Guide to the Drug That Relaxes an Overpowered Heart
In hypertrophic cardiomyopathy the heart is not weak — it is too strong: the muscle is thickened, contracts excessively and in systole blocks its own outflow. Mavacamten was the first drug to target the mechanics themselves: it reduces the number of bridges between actin and myosin, so the heart stops over-contracting. In EXPLORER-HCM it improved functional class and exercise capacity significantly more often than placebo. A short guide: how it works, how to take it, why echocardiography every few weeks is mandatory, who should see a doctor first, and how the newer aficamten differs.

Key points

Mavacamten (brand name Camzyos, Bristol Myers Squibb) is the first-in-class cardiac myosin inhibitor, taken once daily. It is the first to act on the mechanism of excessive contraction itself rather than easing the heart's working conditions.

SituationHow it helpsWhat human studies showed
Symptomatic obstructive hypertrophic cardiomyopathythe outflow obstruction eases, exercise is better tolerated, breathlessness lessensEXPLORER-HCM (Lancet, 2020), phase 3: improved the composite endpoint — functional class and exercise capacity — significantly more often than placebo [1]
Monotherapyhelps even when it is the only drug for this cardiomyopathyan integrated analysis of later data confirms the effect in monotherapy [2]

How it helps

What happens in this disease

Hypertrophic cardiomyopathy is a genetically determined thickening of the heart muscle, most often the interventricular septum. The key misconception: the heart here is not weak but excessively strong.

At molecular level, contraction depends on cross-bridges: myosin heads grab actin filaments and pull. In this disease the proportion of myosin ready to engage is increased — the muscle contracts excessively and relaxes poorly.

Then mechanics take over: in systole the thickened septum together with the anterior mitral leaflet blocks the outflow of blood into the aorta. The resulting outflow tract obstruction produces breathlessness, chest pain, dizziness and syncope.

What was available before, and what changed

ApproachWhat it doesLimitation
Beta blockersLower rate and indirectly force of contractionDo not address the molecular cause; effect often incomplete
Verapamil, disopyramideAffect contractility and fillingTolerability, limited effect
Septal myectomy (surgery)Removes part of the thickened septumSurgery, requires an experienced centre
Alcohol septal ablationInduces a controlled infarct of septal tissueInvasive, risk of conduction block
MavacamtenReduces the number of active actin-myosin bridgesRequires ejection fraction monitoring

Aficamten (Myqorzo): the next generation

MavacamtenAficamten
ClassCardiac myosin inhibitorCardiac myosin inhibitor
Half-lifeLongShorter
TitrationSlower, less frequent stepsFaster and more flexible
Reversibility if over-suppressedSlowerFaster
EvidenceEXPLORER-HCM and subsequent dataSEQUOIA-HCM [3]

How to take it

One capsule a day; the usual start is 5 mg, after which the dose is adjusted by echocardiography.

▸ The effect develops gradually and is judged by exercise tolerance and gradient, not by an immediate sense of relief.
▸ Stopping returns the baseline state — the drug manages the disease rather than curing its genetic cause.

Who should see a doctor first

▸ This is not a general "heart medicine". The indication is narrow: symptomatic obstructive hypertrophic cardiomyopathy confirmed on echocardiography.
▸ Echocardiography is part of the treatment, not a formality. The drug cannot be used without it.

Ejection fraction monitoring

Here benefit and principal risk are the same action at different doses. The drug reduces contractility: in the right measure that is treatment, in excess it is heart failure.

StageWhat happens
Before startingEchocardiography: ejection fraction, outflow tract gradient
StartUsually 5 mg daily
TitrationDose adjusted according to echocardiography and gradient
MaintenanceEchocardiography every 12 weeks
If ejection fraction falls below thresholdTreatment interrupted

The REMS programme. In the US the drug is dispensed only within a restricted-access scheme: prescriber, pharmacy and patient are enrolled and dispensing is tied to a confirmed echocardiography schedule. The logic is straightforward — without monitoring the drug is unsafe, so monitoring is built into the supply chain.

Interactions and limitations

▸ Metabolism runs through CYP2C19 and CYP3A4 — combination with strong inhibitors or inducers requires dose adjustment or is prohibited;
▸ pregnancy is a contraindication; women of childbearing potential need reliable contraception;
▸ heart failure with reduced ejection fraction — the drug is not prescribed;
▸ intercurrent illness (infection, tachyarrhythmia) can lower ejection fraction — therapy is reassessed at such times.

Bottom line

Mavacamten is the first drug to target the mechanics of excessive contraction, and regular echocardiography is what makes treatment safe.

The diagnosis and management can be discussed at a consultation; the product can be ordered here.

References

1. Olivotto I, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759–769. PMID 32871100

2. Olivotto I, et al. Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: an integrated analysis of phase 3 data. Am Heart J. 2026. PMID 42636950

3. Maron MS, et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy (SEQUOIA-HCM). N Engl J Med. 2024;390(20):1849–1861. PMID 38739079

4. CAMZYOS (mavacamten) US Prescribing Information, Bristol Myers Squibb.

Source: Mavacamten (Camzyos): A Short Guide to the Drug That Relaxes an Overpowered Heart — universum.earth. Dr. Pereligyn.

Come back
Request a call back